A Phase 3 interventional study of SNG001 and Placebo in Severe Acute Respiratory Syndrome Coronavirus 2 and COVID-19, sponsored by Synairgen Research Ltd.. Completed at 112 sites in 17 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-03-27.
Sponsored by Synairgen Research Ltd. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing Interferon beta-1a in COVID-19 — 1 open to participants now, 1 under way, 1 of them phase 3. Interferon beta-1a · COVID-19.
Among the 12 studies testing Interferon beta-1a in COVID-19, this one is the 6th largest by enrollment, is one of 3 that started in 2021, is one of 5 in phase 3, and was the 10th registered.
7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.
Browse COVID-19 studies →1 of the 12 studies testing Interferon beta-1a in COVID-19 is open now, in 12 countries. Recruiting first, the newest first:
UMC Utrecht · Sites in United States, Australia, Belgium and 26 more countries
Ages 28 days+
By country, each count listing its studies:
Interferon beta-1a: first FDA approval 1996 (AVONEX), first EMA approval 1997. What it is approved for, and how studies give it, is on its page →
Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 5 · Phase 3 6 · Phase 4 1
First in 2016; this study’s year is marked. 3 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 623 is above the median of 102 across 4,367 interventional studies indexed under COVID-19.
Median enrollment 422 across the 12 interventional studies. Of the 8 that completed or were terminated, 4 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 12 have an industry lead sponsor. The 8 most frequent:
Synairgen Research Ltd. is the lead sponsor of 6 studies on the registry; none are open to participants now.
Synairgen Research Ltd. has 3 studies filed under COVID-19 — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 12 studies testing Interferon beta-1a in COVID-19, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this Phase III study is to confirm that SNG001 can accelerate the recovery of hospitalised patients receiving oxygen with confirmed Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2). Safety and other efficacy endpoints will also be assessed.
Eligible patients with SARS-CoV-2 infection confirmed by a positive virus test and who are hospitalised due to COVID-19 and require oxygen therapy, will be randomised in a 1:1 ratio to receive SNG001 two syringes or placebo two syringes. SNG001 or placebo will be administered via the Ultra nebuliser. Patients will receive a dose of SNG001 or placebo once a day for 14 days and will be followed up for up to 90 days after the first dose of study medication. Study data will be collected from patients daily, as per the study schedule.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
SNG001 via inhalation using Ultra device, once a day for 14 days
Drug: SNG001
Placebo via inhalation using Ultra device, once a day for 14 days
Drug: Placebo
Drug pages: Interferon beta-1a · Interferon Beta-1a Inhalation Solution SNG001
SNG001 nebuliser solution, 2 syringes each containing 0.65 mL once a day
Placebo nebuliser solution, 2 syringes each containing 0.65 mL solution containing excipients of the SNG001 solution
Time to Hospital Discharge
The time to hospital discharge in patients with moderate COVID-19 after administration of SNG001 compared to placebo was evaluated.
Time frame: Day 28
Time to Recovery
Recovery in patients with moderate COVID-19 after administration of SNG001 compared to placebo by time to recovery was evaluated.
Time frame: Day 28
Number of Patients Who Progressed to Severe Disease or Death
The efficacy of SNG001 compared to placebo in patients with moderate COVID-19 by assessing progression to severe disease or death was evaluated. Severe disease was defined by the Ordinal Scale for Clinical Improvement (OSCI) as a score between 5 and 7. Death was defined by an OSCI score of 8.
Time frame: Until Day 35
Number of Patients Who Were Intubated or Who Died
The efficacy of SNG001 compared to placebo in patients with moderate COVID-19 by assessing progression to intubation or death was evaluated. Intubation was defined by the OSCI as a score between 6 and 7. Death was defined by an OSCI score of 8.
Time frame: Until Day 35
Number of Patients Who Died Within 35 Days of First Dose
Patients who died within 35 days of first dose of study intervention were calculated.
Time frame: Until Day 35 of first dose
Cumulative Number of Patients Who Were Discharged From Hospital
The efficacy of SNG001 compared to placebo in patients with moderate COVID-19 was assessed by hospital discharge on given days.
Time frame: Days 7, 14, 21 and 28
Cumulative Number of Patients With Recovery
The efficacy of SNG001 compared to placebo in patients with moderate COVID-19 by assessing recovery was evaluated. Recovery is defined as no limitation of activities according to the Ordinal Scale of Clinical Improvement (OSCI), with no rebound at subsequent assessments.
Time frame: Days 7, 14, 21 and 28
Improvement Based on Entire WHO OSCI Score
The efficacy of SNG001 compared to placebo in patients with moderate COVID-19 by assessing improvement across the entire WHO OSCI were evaluated. Improvement in clinical status is based on the 9-point OSCI score. The score ranges from 0 to 8, where lower score of 0 represents no clinical or virological evidence of infection and higher score of 8 represents death.Higher scores indicated worse outcome.
Time frame: Until Day 35
Change From Baseline in Total Score According to the Breathlessness, Cough and Sputum Scale (BCSS)
The efficacy of SNG001 compared with placebo in patients with moderate COVID-19 by assessing changes in daily breathlessness, cough and sputum scores on a scale of 0 (no symptoms) up to 4 (severe symptoms) was evaluated. Breathlessness, Cough and Sputum is graded on a score from 0 to 4, where a higher score indicates worse symptoms. The total score is calculated by summing the individual scores and is therefore graded on a scale from 0 to 12. Change in value of BCSS total scale, with negative value indicates an improvement in symptoms.
Time frame: Baseline to Day 15
Change From Baseline in National Early Warning Score (NEWS2) During the Hospitalisation Period
The efficacy of SNG001 compared to placebo in patients with moderate COVID-19 by assessing changes in NEWS2 during hospitalisation period was evaluated. It is the sum of scores calculated for Respiratory rate, Oxygen Saturation, Systolic BP, Pulse and Temperature when graded on a scale from 0 to 3 where 0 means a normal assessment and a higher score indicates a greater deviation from normal . 2 more points are added if the patient is receiving oxygen and 3 further points are added if the patient has new-onset confusion, disorientation and/or agitation, where previously their mental state was normal. This gives a score between 0 and 20. Higher scores indicates high clinical risk. Change from baseline in NEWS-2 score, in negative values favors improvement.
Time frame: Day 1 until Day 28
Number of Patients With Presence of COVID-19 Symptoms Based on Daily Assessment
The efficacy of SNG001 compared to placebo in patients with moderate COVID-19 by daily assessment of COVID-19 symptoms was evaluated. The presence of COVID-19 symptoms were assessed. Individual symptoms related to COVID-19/SARS-CoV-2 infection such as fever, breathlessness, and fatigue were assessed.
Time frame: Day 1 until Day 90
Number of Patients With Limitations of Usual Activities Based on Daily Assessment
The efficacy of SNG001 compared to placebo in patients with moderate COVID-19 by daily assessment of limitation of usual activities was evaluated. The patients with limitations of usual activities were the patients who were unable to do usual activities (work, study, housework, family or leisure activities).
Time frame: Day 1 until Day 35
Quality of Life Measured Using EuroQol 5-dimension 5-level (EQ-5D-5L)
The efficacy of SNG001 compared to placebo in patients with moderate COVID-19 by using EQ-5D-5L was evaluated. The EQ-5D-5L provides a simple descriptive profile and a single index value for health status. The EQ-5D-5L self-rated questionnaire includes a visual analogue scale, which records the respondent's self-rated health status on a graduated (0-100) scale, with higher scores for higher health-related quality of life. It also includes the EQ-5D-5L descriptive system, which comprises 5 dimensions of health: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The responses record five levels of severity (no problems/slight problems/moderate problems/severe problems/extreme problems) within a particular EQ-5D dimension. Here, 100 means the best health and 0 means the worst health.
Time frame: Day 0, Day 7, Day 15, Day 28, Day 60 and Day 90
General Anxiety Disorder 7 Questionnaire (GAD-7) Total Score
The efficacy of SNG001 compared to placebo in patients with moderate COVID-19 by assessing long-COVID-19 symptoms was evaluated. Assessment of long-COVID-19 symptoms based on GAD-7 scale. GAD-7 scores seven individual item scales by assigning scores of 0, 1, 2, and 3, to the response categories of "not at all", "several days", "more than half the days", and "nearly every day", respectively. The GAD-7 total score is calculated by summing the individual item scales to give a total score between 0 and 21. Higher score indicates severe anxiety.
Time frame: Day 15, Day 28, Day 60 and Day 90
Functional Assessment of Chronic Illness Therapy Fatigue Scale (FACIT-FS [Version 4]) Total Score
Long-COVID-19 symptoms based on FACIT Fatigue Scale (Version 4) were evaluated. The FACIT Fatigue Scale (Version 4) included statements for patients such as: I feel fatigued; I feel weak all over; I feel listless ("washed out"); I feel tired; I have trouble starting things because I am tired; I have trouble finishing things because I am tired; I have energy; I am able to do my usual activities; I need to sleep during the day; I am too tired to eat; I need help doing my usual activities; and I am frustrated by being too tired to do the things I want to do. Based on responses on above statements, scoring was done and scores ranges from 0 to 4, where 0 represents not at all bothered by any of the above problems and 4 indicates very much bothered every day by any of the above problems. Total scores will be calculated as per the algorithm to give a total score on a scale between 0 and 52, where a higher total score indicates lower level of fatigue.
Time frame: Day 15, Day 28, Day 60 and Day 90
Patient Health Questionnaire-9 (PHQ-9) Total Score
Long-COVID-19 symptoms based on PHQ-9 were evaluated. Patient Health Questionnaire-9 (PHQ-9) scores nine individual item scales by assigning scores of 0, 1, 2, and 3, to the response categories of "not at all", "several days", "more than half the days", and "nearly every day", respectively. PHQ-9 total scores are calculated by summing the individual item scales to give a total score between 0 and 27. Higher scores indicated worse outcome.
Time frame: Day 15, Day 28, Day 60 and Day 90
Overall Pain Severity as Measured by Brief Pain Inventory Composite Scores
Brief Pain Inventory Composite Scores is a self administered questionnaire that assesses pain interference. Overall pain severity score is calculated as the mean of questions of the brief pain inventory. The overall pain severity score is the average pain, on a scale from 0 to 10 of the worst pain, least pain and average pain in the last 24 hours and pain right now scores. Here, 0 indicates "No pain" and 10 indicates "Worst pain".
Time frame: Day 15, Day 28, Day 60 and Day 90
Number of Patients With Adverse Events (AEs) and Serious Adverse Events (SAEs)
The general safety and tolerability of SNG001 compared to placebo when administered to patients with moderate COVID-19 by assessing number of patients with AEs was assessed.
Time frame: From the day informed consent is obtained until 28 days after the last administration of the study medication (Day 90)
This trial was conducted at 112 centers which included 623 patients across 17 countries. The trial began on 12 January 2021 (first patient consented) and was completed on 10 Feb 2022.
| Milestone | SNG001 | Placebo |
|---|---|---|
| Started | 309 | 314 |
| Completed | 233 | 231 |
| Not completed | 76 | 83 |
| Withdrew: Withdrawal by subject | 23 | 27 |
| Withdrew: Protocol violation | 0 | 1 |
| Withdrew: Non-compliance | 0 | 2 |
| Withdrew: Physician decision | 2 | 1 |
| Withdrew: Serious adverse event (fatal) | 16 | 18 |
| Withdrew: Serious adverse event (non fatal) | 2 | 1 |
| Withdrew: Non-serious adverse event | 1 | 3 |
| Withdrew: Lost to follow-up | 26 | 27 |
| Withdrew: Other | 6 | 3 |
The time to hospital discharge in patients with moderate COVID-19 after administration of SNG001 compared to placebo was evaluated.
| days | SNG001 | Placebo |
|---|---|---|
| Time to Hospital Discharge | 7.0 (7.0 to 8.0) | 8.0 (7.0 to 9.0) |
Recovery in patients with moderate COVID-19 after administration of SNG001 compared to placebo by time to recovery was evaluated.
| days | SNG001 | Placebo |
|---|---|---|
| Time to Recovery | 25.0 (22.0 to NA) | 25.0 (22.0 to NA) |
The efficacy of SNG001 compared to placebo in patients with moderate COVID-19 by assessing progression to severe disease or death was evaluated. Severe disease was defined by the Ordinal Scale for Clinical Improvement (OSCI) as a score between 5 and 7. Death was defined by an OSCI score of 8.
| Participants | SNG001 | Placebo |
|---|---|---|
| Number of Patients Who Progressed to Severe Disease or Death | 33 | 45 |
The efficacy of SNG001 compared to placebo in patients with moderate COVID-19 by assessing progression to intubation or death was evaluated. Intubation was defined by the OSCI as a score between 6 and 7. Death was defined by an OSCI score of 8.
| Participants | SNG001 | Placebo |
|---|---|---|
| Number of Patients Who Were Intubated or Who Died | 20 | 23 |
Patients who died within 35 days of first dose of study intervention were calculated.
| Participants | SNG001 | Placebo |
|---|---|---|
| Number of Patients Who Died Within 35 Days of First Dose | 14 | 17 |
The efficacy of SNG001 compared to placebo in patients with moderate COVID-19 was assessed by hospital discharge on given days.
| Participants | SNG001 | Placebo |
|---|---|---|
| Day 7 | 154 | 141 |
| Day 14 | 231 | 223 |
| Day 21 | 245 | 249 |
| Day 28 | 249 | 255 |
The efficacy of SNG001 compared to placebo in patients with moderate COVID-19 by assessing recovery was evaluated. Recovery is defined as no limitation of activities according to the Ordinal Scale of Clinical Improvement (OSCI), with no rebound at subsequent assessments.
| Participants | SNG001 | Placebo |
|---|---|---|
| Day 7 | 28 | 17 |
| Day 14 | 75 | 73 |
| Day 21 | 117 | 118 |
| Day 28 | 145 | 151 |
The efficacy of SNG001 compared to placebo in patients with moderate COVID-19 by assessing improvement across the entire WHO OSCI were evaluated. Improvement in clinical status is based on the 9-point OSCI score. The score ranges from 0 to 8, where lower score of 0 represents no clinical or virological evidence of infection and higher score of 8 represents death.Higher scores indicated worse outcome.
| Participants | SNG001 | Placebo |
|---|---|---|
| Baseline — 0 = No clinical or virological evidence of infection | 0 | 0 |
| Baseline — 1 = No limitations of activities | 0 | 0 |
| Baseline — 2 = Limitation of activities | 1 | 0 |
| Baseline — 3 = Hospitalised - no oxygen therapy | 3 | 8 |
| Baseline — 4 = Oxygen by mask, or nasal prongs | 304 | 304 |
| Baseline — 5 = Non-invasive ventilation, or high flow oxygen | 1 | 2 |
| Baseline — 6 = Intubation and mechanical ventilation | 0 | 0 |
| Baseline — 7 = Ventilation plus additional organ support | 0 | 0 |
| Baseline — 8 = Death | 0 | 0 |
| Baseline — Missing | 0 | 0 |
| Day 7 — 0 = No clinical or virological evidence of infection | 20 | 14 |
| Day 7 — 1 = No limitations of activities | 18 | 12 |
| Day 7 — 2 = Limitation of activities | 115 | 114 |
| Day 7 — 3 = Hospitalised - no oxygen therapy | 42 | 42 |
| Day 7 — 4 = Oxygen by mask, or nasal prongs | 53 | 69 |
| Day 7 — 5 = Non-invasive ventilation, or high flow oxygen | 18 | 26 |
| Day 7 — 6 = Intubation and mechanical ventilation | 2 | 2 |
| Day 7 — 7 = Ventilation plus additional organ support | 3 | 3 |
| Day 7 — 8 = Death | 4 | 0 |
| Day 7 — Missing | 34 | 32 |
| Day 14 — 0 = No clinical or virological evidence of infection | 62 | 57 |
| Day 14 — 1 = No limitations of activities | 24 | 30 |
| Day 14 — 2 = Limitation of activities | 135 | 127 |
| Day 14 — 3 = Hospitalised - no oxygen therapy | 11 | 18 |
| Day 14 — 4 = Oxygen by mask, or nasal prongs | 13 | 15 |
| Day 14 — 5 = Non-invasive ventilation, or high flow oxygen | 2 | 4 |
| Day 14 — 6 = Intubation and mechanical ventilation | 3 | 1 |
| Day 14 — 7 = Ventilation plus additional organ support | 3 | 9 |
| Day 14 — 8 = Death | 9 | 7 |
| Day 14 — Missing | 47 | 46 |
| Day 21 — 0 = No clinical or virological evidence of infection | 89 | 94 |
| Day 21 — 1 = No limitations of activities | 32 | 23 |
| Day 21 — 2 = Limitation of activities | 109 | 114 |
| Day 21 — 3 = Hospitalised - no oxygen therapy | 3 | 4 |
| Day 21 — 4 = Oxygen by mask, or nasal prongs | 7 | 4 |
| Day 21 — 5 = Non-invasive ventilation, or high flow oxygen | 1 | 0 |
| Day 21 — 6 = Intubation and mechanical ventilation | 2 | 1 |
| Day 21 — 7 = Ventilation plus additional organ support | 2 | 8 |
| Day 21 — 8 = Death | 12 | 9 |
| Day 21 — Missing | 52 | 57 |
| Day 28 — 0 = No clinical or virological evidence of infection | 123 | 134 |
| Day 28 — 1 = No limitations of activities | 23 | 13 |
| Day 28 — 2 = Limitation of activities | 85 | 95 |
| Day 28 — 3 = Hospitalised - no oxygen therapy | 0 | 0 |
| Day 28 — 4 = Oxygen by mask, or nasal prongs | 3 | 2 |
| Day 28 — 5 = Non-invasive ventilation, or high flow oxygen | 4 | 0 |
| Day 28 — 6 = Intubation and mechanical ventilation | 0 | 1 |
| Day 28 — 7 = Ventilation plus additional organ support | 1 | 3 |
| Day 28 — 8 = Death | 14 | 14 |
| Day 28 — Missing | 56 | 52 |
| Day 35 — 0 = No clinical or virological evidence of infection | 147 | 153 |
| Day 35 — 1 = No limitations of activities | 10 | 16 |
| Day 35 — 2 = Limitation of activities | 71 | 73 |
| Day 35 — 3 = Hospitalised - no oxygen therapy | 0 | 0 |
| Day 35 — 4 = Oxygen by mask, or nasal prongs | 2 | 1 |
| Day 35 — 5 = Non-invasive ventilation, or high flow oxygen | 1 | 0 |
| Day 35 — 6 = Intubation and mechanical ventilation | 2 | 1 |
| Day 35 — 7 = Ventilation plus additional organ support | 1 | 1 |
| Day 35 — 8 = Death | 14 | 17 |
| Day 35 — Missing | 61 | 52 |
The efficacy of SNG001 compared with placebo in patients with moderate COVID-19 by assessing changes in daily breathlessness, cough and sputum scores on a scale of 0 (no symptoms) up to 4 (severe symptoms) was evaluated. Breathlessness, Cough and Sputum is graded on a score from 0 to 4, where a higher score indicates worse symptoms. The total score is calculated by summing the individual scores and is therefore graded on a scale from 0 to 12. Change in value of BCSS total scale, with negative value indicates an improvement in symptoms.
| score on a scale | SNG001 | Placebo |
|---|---|---|
| Change From Baseline in Total Score According to the Breathlessness, Cough and Sputum Scale (BCSS) | -2.1 ± 0.09 | -2.2 ± 0.09 |
The efficacy of SNG001 compared to placebo in patients with moderate COVID-19 by assessing changes in NEWS2 during hospitalisation period was evaluated. It is the sum of scores calculated for Respiratory rate, Oxygen Saturation, Systolic BP, Pulse and Temperature when graded on a scale from 0 to 3 where 0 means a normal assessment and a higher score indicates a greater deviation from normal . 2 more points are added if the patient is receiving oxygen and 3 further points are added if the patient has new-onset confusion, disorientation and/or agitation, where previously their mental state was normal. This gives a score between 0 and 20. Higher scores indicates high clinical risk. Change from baseline in NEWS-2 score, in negative values favors improvement.
| score on a scale | SNG001 | Placebo |
|---|---|---|
| Day 7 | -0.7 ± 3.08 | -0.7 ± 2.55 |
| Day 14 | 0.2 ± 3.83 | -0.3 ± 3.32 |
| Day 21 | 2.8 ± 3.16 | 2.3 ± 3.62 |
| Day 28 | -0.5 ± 2.08 | 4.5 ± 4.37 |
The efficacy of SNG001 compared to placebo in patients with moderate COVID-19 by daily assessment of COVID-19 symptoms was evaluated. The presence of COVID-19 symptoms were assessed. Individual symptoms related to COVID-19/SARS-CoV-2 infection such as fever, breathlessness, and fatigue were assessed.
| Participants | SNG001 | Placebo |
|---|---|---|
| Baseline | 306 | 310 |
| Day 7 | 221 | 234 |
| Day 14 | 169 | 162 |
| Day 21 | 154 | 139 |
| Day 28 | 122 | 117 |
| Day 35 | 61 | 69 |
| Day 60 | 44 | 57 |
| Day 90 | 41 | 51 |
The efficacy of SNG001 compared to placebo in patients with moderate COVID-19 by daily assessment of limitation of usual activities was evaluated. The patients with limitations of usual activities were the patients who were unable to do usual activities (work, study, housework, family or leisure activities).
| Participants | SNG001 | Placebo |
|---|---|---|
| Day 1 | 0 | 1 |
| Day 7 | 115 | 114 |
| Day 14 | 135 | 127 |
| Day 21 | 109 | 114 |
| Day 28 | 85 | 95 |
| Day 35 | 71 | 73 |
The efficacy of SNG001 compared to placebo in patients with moderate COVID-19 by using EQ-5D-5L was evaluated. The EQ-5D-5L provides a simple descriptive profile and a single index value for health status. The EQ-5D-5L self-rated questionnaire includes a visual analogue scale, which records the respondent's self-rated health status on a graduated (0-100) scale, with higher scores for higher health-related quality of life. It also includes the EQ-5D-5L descriptive system, which comprises 5 dimensions of health: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The responses record five levels of severity (no problems/slight problems/moderate problems/severe problems/extreme problems) within a particular EQ-5D dimension. Here, 100 means the best health and 0 means the worst health.
| score on a scale | SNG001 | Placebo |
|---|---|---|
| Day 0 | 56.4 ± 21.72 | 56.9 ± 20.95 |
| Day 7 | 72.6 ± 18.39 | 71.1 ± 20.44 |
| Day 15 | 79.5 ± 18.25 | 79.0 ± 16.51 |
| Day 28 | 83.3 ± 16.00 | 83.5 ± 14.90 |
| Day 60 | 88.9 ± 14.16 | 88.0 ± 13.56 |
| Day 90 | 90.3 ± 12.65 | 89.9 ± 13.65 |
The efficacy of SNG001 compared to placebo in patients with moderate COVID-19 by assessing long-COVID-19 symptoms was evaluated. Assessment of long-COVID-19 symptoms based on GAD-7 scale. GAD-7 scores seven individual item scales by assigning scores of 0, 1, 2, and 3, to the response categories of "not at all", "several days", "more than half the days", and "nearly every day", respectively. The GAD-7 total score is calculated by summing the individual item scales to give a total score between 0 and 21. Higher score indicates severe anxiety.
| score on a scale | SNG001 | Placebo |
|---|---|---|
| Day 15 | 3.3 ± 4.08 | 3.5 ± 4.30 |
| Day 28 | 2.2 ± 3.67 | 1.9 ± 3.29 |
| Day 60 | 1.4 ± 3.06 | 1.7 ± 3.38 |
| Day 90 | 1.0 ± 2.41 | 1.6 ± 3.43 |
Long-COVID-19 symptoms based on FACIT Fatigue Scale (Version 4) were evaluated. The FACIT Fatigue Scale (Version 4) included statements for patients such as: I feel fatigued; I feel weak all over; I feel listless ("washed out"); I feel tired; I have trouble starting things because I am tired; I have trouble finishing things because I am tired; I have energy; I am able to do my usual activities; I need to sleep during the day; I am too tired to eat; I need help doing my usual activities; and I am frustrated by being too tired to do the things I want to do. Based on responses on above statements, scoring was done and scores ranges from 0 to 4, where 0 represents not at all bothered by any of the above problems and 4 indicates very much bothered every day by any of the above problems. Total scores will be calculated as per the algorithm to give a total score on a scale between 0 and 52, where a higher total score indicates lower level of fatigue.
| score on a scale | SNG001 | Placebo |
|---|---|---|
| Day 15 | 39.1 ± 9.79 | 38.7 ± 10.31 |
| Day 28 | 42.5 ± 10.19 | 42.8 ± 8.98 |
| Day 60 | 46.4 ± 8.22 | 45.5 ± 7.96 |
| Day 90 | 46.9 ± 8.01 | 46.3 ± 7.78 |
Long-COVID-19 symptoms based on PHQ-9 were evaluated. Patient Health Questionnaire-9 (PHQ-9) scores nine individual item scales by assigning scores of 0, 1, 2, and 3, to the response categories of "not at all", "several days", "more than half the days", and "nearly every day", respectively. PHQ-9 total scores are calculated by summing the individual item scales to give a total score between 0 and 27. Higher scores indicated worse outcome.
| score on a scale | SNG001 | Placebo |
|---|---|---|
| Day 15 | 4.6 ± 4.47 | 5.0 ± 4.71 |
| Day 28 | 3.2 ± 4.15 | 3.1 ± 4.02 |
| Day 60 | 1.7 ± 3.23 | 2.1 ± 3.85 |
| Day 90 | 1.5 ± 3.05 | 2.0 ± 3.89 |
Brief Pain Inventory Composite Scores is a self administered questionnaire that assesses pain interference. Overall pain severity score is calculated as the mean of questions of the brief pain inventory. The overall pain severity score is the average pain, on a scale from 0 to 10 of the worst pain, least pain and average pain in the last 24 hours and pain right now scores. Here, 0 indicates "No pain" and 10 indicates "Worst pain".
| score on a scale | SNG001 | Placebo |
|---|---|---|
| Day 15 | 3.4 ± 2.13 | 3.3 ± 1.98 |
| Day 28 | 3.2 ± 1.98 | 3.2 ± 1.77 |
| Day 60 | 4.1 ± 1.54 | 3.3 ± 1.94 |
| Day 90 | 4.5 ± 2.14 | 3.5 ± 2.33 |
The general safety and tolerability of SNG001 compared to placebo when administered to patients with moderate COVID-19 by assessing number of patients with AEs was assessed.
| Participants | SNG001 | Placebo |
|---|---|---|
| Any Treatment-emergent adverse event (TEAE) | 251 | 251 |
| Any serious TEAE | 38 | 55 |
| Any serious related TEAE | 3 | 3 |
| Any fatal TEAE | 16 | 16 |
| Any fatal TEAE related to study treatment | 0 | 0 |
| Any TEAE related to study treatment | 68 | 77 |
| Any TEAE leading to discontinuation of study treatment | 24 | 23 |
| Any Adverse Events of Note | 0 | 1 |
Collected over From the day informed consent is obtained until 28 days after the last administration of the study medication (Day 90).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| SNG001 | 16/309 (5.2%) | 38/301 (12.6%) | 250/301 (83.1%) |
| Placebo | 18/314 (5.7%) | 55/303 (18.2%) | 248/303 (81.8%) |
| Event | SNG001 | Placebo |
|---|---|---|
| COVID-19Infections and infestations | 11/301 | 8/303 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 9/301 | 9/303 |
| COVID-19 pneumoniaInfections and infestations | 8/301 | 8/303 |
| Acute respiratory failureRespiratory, thoracic and mediastinal disorders | 1/301 | 7/303 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 0/301 | 5/303 |
| PneumoniaInfections and infestations | 3/301 | 0/303 |
| Acute kidney injuryRenal and urinary disorders | 3/301 | 2/303 |
| Acute myocardial infarctionCardiac disorders | 2/301 | 1/303 |
| Acute respiratory distress syndromeRespiratory, thoracic and mediastinal disorders | 2/301 | 1/303 |
| Cardiac arrestCardiac disorders | 1/301 | 2/303 |
| Event | SNG001 | Placebo |
|---|---|---|
| Productive coughRespiratory, thoracic and mediastinal disorders | 70/301 | 72/303 |
| HeadacheNervous system disorders | 71/301 | 61/303 |
| MyalgiaMusculoskeletal and connective tissue disorders | 60/301 | 60/303 |
| RhinorrhoeaRespiratory, thoracic and mediastinal disorders | 58/301 | 54/303 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 55/301 | 47/303 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 54/301 | 54/303 |
| Chest painGeneral disorders | 36/301 | 52/303 |
| WheezingRespiratory, thoracic and mediastinal disorders | 45/301 | 35/303 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 30/301 | 41/303 |
| FatigueGeneral disorders | 39/301 | 40/303 |
The Intent-to-Treat (ITT) analysis population consisted of all randomised patients.
| Age, Continuous(years) | SNG001 | Placebo | Total |
|---|---|---|---|
| Mean | 52 ± 15.19 | 53.7 ± 14.42 | 52.8 ± 14.82 |
| Sex: Female, Male(Participants) | SNG001 | Placebo | Total |
|---|---|---|---|
| Female | 203 | 208 | 411 |
| Male | 106 | 106 | 212 |
| Ethnicity (NIH/OMB)(Participants) | SNG001 | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 53 | 49 | 102 |
| Not Hispanic or Latino | 238 | 242 | 480 |
| Unknown or Not Reported | 18 | 23 | 41 |
| Race/Ethnicity, Customized(Participants) | SNG001 | Placebo | Total |
|---|---|---|---|
| White | 224 | 215 | 439 |
| Black | 7 | 6 | 13 |
| Asian- Chinese | 2 | 2 | 4 |
| Asian- Other | 40 | 46 | 86 |
| Arab | 2 | 5 | 7 |
| American Indian | 5 | 5 | 10 |
| Other | 10 | 13 | 23 |
| Unknown | 19 | 22 | 41 |
Showing the first 100 of 112 sites across 17 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided
Ran from Jan 2021 to primary completion in Dec 2021, 11 months.
Results were first posted in Mar 2023, 1 year 3 months after primary completion.
Of 168 industry-sponsored phase 3 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's 11 months is above that.
Counting every sponsor, half of 453 studies reached it within 9 months; a quarter within 4 and three quarters within 17.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Interferon beta-1a · Interferon Beta-1a Inhalation Solution SNG001
Synairgen Research Ltd.